This Medudy course is a video tutorial for physicians on the topic of "PSA in transgender women on estrogen". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Transsexual women who receive oestrogen and develop prostate cancer are more likely to develop high-grade disease than cis men. This indicates a delay in diagnosis. One possible reason for the delayed diagnosis could be the lack of PSA reference ranges, which apply specifically to transgender women undergoing gender reassignment hormone therapy. The castrating effect of sex reassignment hormone therapy is expected to lower PSA, the production of which is regulated by androgens.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
